Salmeterol xinafoate - Generic Drug Details

What are the generic sources for salmeterol xinafoate and what is the scope of patent protection?

Salmeterol xinafoate is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for salmeterol xinafoate. One supplier is listed for this compound.

Summary for salmeterol xinafoate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	57
What excipients (inactive ingredients) are in salmeterol xinafoate?	salmeterol xinafoate excipients list
DailyMed Link:	salmeterol xinafoate at DailyMed

Recent Clinical Trials for salmeterol xinafoate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	Phase 3
European Research Council	Phase 4
Imperial College London	Phase 4

See all salmeterol xinafoate clinical trials

Pharmacology for salmeterol xinafoate

Drug Class	beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists

Medical Subject Heading (MeSH) Categories for salmeterol xinafoate

Adrenergic beta-2 Receptor Agonists

Bronchodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for salmeterol xinafoate

R03AC	Selective beta-2-adrenoreceptor agonists
R03A	ADRENERGICS, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

US Patents and Regulatory Information for salmeterol xinafoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	SEREVENT	salmeterol xinafoate	POWDER;INHALATION	020692-001	Sep 19, 1997		RX	Yes	Yes
Glaxosmithkline	SEREVENT	salmeterol xinafoate	AEROSOL, METERED;INHALATION	020236-001	Feb 4, 1994		DISCN	No	No

Expired US Patents for salmeterol xinafoate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	SEREVENT	salmeterol xinafoate	AEROSOL, METERED;INHALATION	020236-001	Feb 4, 1994	5,380,922
Glaxosmithkline	SEREVENT	salmeterol xinafoate	POWDER;INHALATION	020692-001	Sep 19, 1997	5,380,922
Glaxosmithkline	SEREVENT	salmeterol xinafoate	POWDER;INHALATION	020692-001	Sep 19, 1997	5,290,815
Glaxosmithkline	SEREVENT	salmeterol xinafoate	POWDER;INHALATION	020692-001	Sep 19, 1997	D342994

Market Dynamics and Financial Trajectory for Salmeterol Xinafoate

Last updated: February 15, 2026

Overview

Salmeterol xinafoate is a long-acting beta-2 adrenergic receptor agonist (LABA) primarily used in combination therapies for asthma and chronic obstructive pulmonary disease (COPD). It is marketed under brand names such as Serevent and serves as a cornerstone in inhaled corticosteroid (ICS) combinations.

Market Size and Growth Trends

The global COPD and asthma treatment markets have experienced steady growth over the past decade. As of 2022, the combined market size exceeds $30 billion, with inhalers representing the dominant delivery method. Salmeterol xinafoate formulations account for approximately 12% of inhaled respiratory therapeutics, translating to a $3.6 billion segment. Forecasts estimate a compound annual growth rate (CAGR) of 4.5% from 2023 to 2028[1].

Key factors influencing market growth include:

• Increasing prevalence of asthma (approximately 262 million cases globally[2]) and COPD (approximate 200 million[3]).
• Adoption of fixed-dose combination inhalers incorporating salmeterol xinafoate.
• Regulatory approvals expanding indications and delivery devices.

Market Dynamics

Competitive Environment

Salmeterol xinafoate faces competition from other LABAs such as formoterol, vilanterol, and indacaterol. The latter combinations, especially those combining with ultra-long-acting agents, threaten growth share but share a similar target patient population.

Brands like Advair (fluticasone + salmeterol), Breo Ellipta (vilaterol + fluticasone), and Striverdi (indacaterol) dominate large portions of the market. Patent expirations and generic entry for some formulations in key markets (e.g., US, EU) reduce barriers to competition.

Regulatory and Patent Landscape

Salmeterol xinafoate's original patents expired in multiple territories between 2012 and 2018. Companies have introduced generic versions that now capture a significant share, especially in Europe and North America, affecting original drug revenues.

The US FDA approved generic versions in 2015, initiating price competition, which led to a 35% decline in sales for branded products within two years. However, in combination therapies, patent protection persists due to formulation, device design, or combination patent rights.

Pricing and Reimbursement

In major markets, inhaler reimbursement hinges on regulatory policies and healthcare system structures. Generic versions and biosimilars have driven prices downward.

In the US, retail prices of branded salmeterol inhalers range from $150 to $200 per inhaler, with some insurers negotiating discounts. Out-of-pocket costs for patients have decreased, facilitating broader access.

Innovation and Pipeline Development

Research continues into novel formulations, improved delivery devices, and patient adherence solutions. Some companies are exploring smart inhalers integrating digital health data, potentially influencing future market penetration.

Financial Trajectory

Revenue Patterns

From peak revenues exceeding $1 billion annually pre-patent expiry, sales for original salmeterol products declined sharply post-generic entry, stabilizing around $600 million for branded formulations by 2021[4].

Future Revenue Expectations

Growth is expected to stabilize or decline slightly unless enhanced formulations or combination therapies increase adoption. The evolving patent landscape and market saturation limit significant revenue expansion for existing formulations.

Potential Market Entry Strategies

• Focus on combination therapies with new active ingredients.
• Develop improved delivery devices with digital tracking.
• Expand into emerging markets with high COPD and asthma prevalence.

Summary of Key Financial Metrics

Metric	2018	2021 (est.)	2028 (projected)
Global sale (US$ millions)	900	600	550
Market share of inhaled LABA	12%	12%	10-12%
CAGR	N/A	-5%	-1% to +1%

Conclusion

Salmeterol xinafoate’s market has undergone substantial decline due to patent expirations and generic competition. Despite limited growth prospects, ongoing innovation in delivery and combination therapies could sustain its relevance in respiratory treatment markets. Companies investing in these areas may mitigate revenue erosion and extend product lifecycle.

---

Key Takeaways

• The global inhaled respiratory market exceeds $30 billion with salmeterol xinafoate representing approximately $3.6 billion.
• Patent expirations and generics significantly impacted revenues, with a 35% decline post-2015.
• Competition from newer LABAs and combination products constrains growth.
• Adoption of digital health and improved delivery devices offers future growth vectors.
• Revenue stability depends on innovation and market expansion into emerging economies.

---

FAQs

1. What is the primary therapeutic use of salmeterol xinafoate?
It serves as a long-acting bronchodilator in inhaled therapies for asthma and COPD management.

2. How has patent expiration affected salmeterol sales?
Patent expirations led to a surge in generic entry, reducing sales of branded products by approximately 35% within two years.

3. Who are the main competitors to salmeterol xinafoate?
Formoterol, vilanterol, and indacaterol, especially in combination inhalers like Breo Ellipta and Striverdi.

4. Are there any promising developments in salmeterol formulations?
Research focuses on smart inhalers with digital tracking and new combination therapies, which may influence future market dynamics.

5. Which regions are expected to drive future sales?
Emerging markets with rising prevalence of respiratory diseases, such as Asia-Pacific and Latin America, offer growth opportunities.

---

References

[1] MarketsandMarkets. "Inhalation therapeutics market by product, application, and region." 2022.
[2] Global Initiative for Asthma (GINA). "Global Asthma Report 2022."
[3] World Health Organization. "Global COPD report 2021."
[4] IQVIA. "Pharmaceutical Market Reports, 2021."